Advertisement

Archives of Gynecology and Obstetrics

, Volume 288, Issue 4, pp 731–737 | Cite as

Androgen therapy in women: for whom and when

  • Nicola Pluchino
  • Arianna Carmignani
  • Alessandra Cubeddu
  • Anna Santoro
  • Vito Cela
  • Tania Errasti Alcalà
General Gynecology

Abstract

Androgens play a primary role in female physiopathology. The age-related reduction in the production of ovarian and adrenal androgens may significantly affect women’s health. The decline of circulating androgens results from a combination of two events: reduced ovarian production and aged-related decline in adrenal androgen synthesis. The relative androgen deficiency in pre- and postmenopausal women may induce impairment of sexual function, libido, well-being, energy and may contribute to reduced cognitive functions. Whether androgen deficiency also affects cardiovascular or bone biology in women during reproductive aging is still controversial. Both in the central nervous system and peripheral tissues, there are multiple ways whereby androgens target their specific actions through a particular tropism of the brain areas that are involved in sexual function, behavior and cognition. Among circulating available androgens that are involved in several domains of sexual response, adrenal androgens seem to be related to some sexual symptoms as well as diminished cognitive function in postmenopausal women. The possibilities of treating low sexual desire/hypoactive sexual desire disorder are multifaceted and should include the combination of both pharmacological treatments able to maximize biological signals that drive the sexual response as well as individualized psychosocial therapies to overcome personal and relational difficulties. Transdermal testosterone has been proved to be effective but the use of additional treatment like oral or vaginal dehydroepiandrosterone is still controversial, despite many evidences support it. The decision to treat premenopausal or postmenopausal women with signs/symptoms of androgen insufficiency is mainly based on the clinical judgment, together with estrogens co-administration and following informed consent related to the unknown long-term risks.

Keywords

Testosterone DHEA/S Reproductive aging 

Notes

Conflict of interest

None.

References

  1. 1.
    Davis SR, Panjari M, Stanczyk FZ (2011) DHEA replacement for postmenopausal women. J Clin Endocrinol Metab 96:1642–1653PubMedCrossRefGoogle Scholar
  2. 2.
    Davison SL, Bell R, Donath S, Montalto JG, Davis SR (2005) Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 90:3847–3853PubMedCrossRefGoogle Scholar
  3. 3.
    Labrie C, Bélanger A, Labrie F (1988) Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 123:1412–1417PubMedCrossRefGoogle Scholar
  4. 4.
    Labrie F (2003) Extragonadal synthesis of sex steroids: intracrinology. Ann Endocrinol (Paris) 64:95–107Google Scholar
  5. 5.
    Judd HL, Judd GE, Lucas WE, Yen SS (1974) Endocrine function of the postmenopausal ovary concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 39:1020–1024PubMedCrossRefGoogle Scholar
  6. 6.
    Rabinovici J, Rothman P, Monroe SE, Nerenberg C, Jaffe RB (1992) Endocrine effects and pharmacokinetic characteristics of a potent new GnRH antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. J Endocrinol Metab 75:1220–1225CrossRefGoogle Scholar
  7. 7.
    Judd HL, Lucas WE, Yen SS (1974) Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 118:793–798PubMedGoogle Scholar
  8. 8.
    Couzinet B, Meduri G, Lecce MG, Young J, Brailly S, Loosfelt H et al (2001) The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 86:5060–5066PubMedCrossRefGoogle Scholar
  9. 9.
    Liu CH, Laughlin GA, Fischer UG, Yen SS (1990) Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17,20 desmolase enzymatic activity. J Clin Endocrinol Metab 71:900–907PubMedCrossRefGoogle Scholar
  10. 10.
    Couch RM, Muller J, Winter JS (1986) Regulation of the activities of 17-hydroxylase and 17,20-desmolase in the human adrenal cortex: kinetic analysis and inhibition by endogenous steroids. J Clin Endocrinol Metab 63:613–618PubMedCrossRefGoogle Scholar
  11. 11.
    Mortola JF, Yen SS (1990) The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 71:696–704PubMedCrossRefGoogle Scholar
  12. 12.
    Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994) Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360–1367PubMedCrossRefGoogle Scholar
  13. 13.
    Luu-The V, Dufort I, Pelletier G, Labrie F (2001) Type 5 17 beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women. Mol Cell Endocrinol 171:77–82PubMedCrossRefGoogle Scholar
  14. 14.
    Al-Azzawia F, Palacios S (2009) Hormonal changes during menopause. Maturitas 63:135–137CrossRefGoogle Scholar
  15. 15.
    Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L et al (2002) Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 77:660–665PubMedCrossRefGoogle Scholar
  16. 16.
    Shifren JL, Davis SR, Dennerstein L, Heiman JR, Lobo RA, Simon JA (2005) The role of testosterone therapy in postmenopausal women: position statement of the North American Menopause Society. Menopause 12:497–511CrossRefGoogle Scholar
  17. 17.
    Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W et al (2006) Androgen therapy in women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91:3696–3710CrossRefGoogle Scholar
  18. 18.
    Wylie K, Rees M, Hackett G, Anderson R, Bouloux PM, Cust M et al (2010) Androgens, health and sexuality in women and men. Review. Maturitas 67:275–289PubMedCrossRefGoogle Scholar
  19. 19.
    Schwenkhagena A, Studdb J (2009) Role of testosterone in the treatment of hypoactive sexual desire disorder. Maturitas 63:152–159CrossRefGoogle Scholar
  20. 20.
    Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J et al (2000) Report of the International Consensus Development Conference on Female Sexual Dysfunction: definitions and classifications. J Urol 163:888–893PubMedCrossRefGoogle Scholar
  21. 21.
    Braunstein GD (2006) Androgen insufficiency in women. Growth Horm IGF Res 16 (Suppl A): S109–17Google Scholar
  22. 22.
    Turna B, Apaydin E, Semerci B, Altay B, Civili N, Nazli O (2005) Women with low libido: correlation of decreased androgen levels with female sexual function index. Int J Impot Res 17:148–153PubMedCrossRefGoogle Scholar
  23. 23.
    Guay A, Jacobson J, Munarriz R, Traish A, Talakoub L, Quirk F et al (2004) Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: part B. Reduced serum androgen levels in healthy premenopausal women with complaints of sexual dysfunction. Int J Impot Res 16:121–129PubMedCrossRefGoogle Scholar
  24. 24.
    Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB, Korenman S et al (2005) Correlates of circulating androgens in mid-life women: the study of women’s health across the nation. J Clin Endocrinol Metab 90:4836–4845PubMedCrossRefGoogle Scholar
  25. 25.
    Basson R, Brotto LA, Petkau AJ, Labrie F (2010) Role of androgens in women’s sexual dysfunction. Menopause 17:962–971PubMedCrossRefGoogle Scholar
  26. 26.
    Davis SR, Davison SL, Donath S, Bell RJ (2005) Circulating androgen levels and self-reported sexual function in women. JAMA 294:91–96PubMedCrossRefGoogle Scholar
  27. 27.
    Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M et al (2008) Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 359:2005–2017PubMedCrossRefGoogle Scholar
  28. 28.
    Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I et al (2010) Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 13:121–131PubMedCrossRefGoogle Scholar
  29. 29.
    Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA et al (2005) Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 165:1582–1589PubMedCrossRefGoogle Scholar
  30. 30.
    Goldstat R, Briganti E, Tran J et al (2003) Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 10:390–398PubMedCrossRefGoogle Scholar
  31. 31.
    Davis S, Papalia MA, Norman RJ, O’Neill S, Redelman M, Williamson M et al (2008) Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med 148:569–577PubMedCrossRefGoogle Scholar
  32. 32.
    Braunstein GD (2007) The Endocrine Society Clinical Practice Guideline and The North American Menopause Society position statement on androgen therapy in women: another one of Yogi’s forks. J Clin Endocrinol Metab 92:4091–4093PubMedCrossRefGoogle Scholar
  33. 33.
    Lobo RA (2001) Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv 56:361–376PubMedCrossRefGoogle Scholar
  34. 34.
    Moutos D, Smith S, Zacur H (1995) The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial. Contraception 52:105–109PubMedCrossRefGoogle Scholar
  35. 35.
    Carlstrom K, Karlsson R, Von Schoultz B (2002) Diurnal rhythm and effects of oral contraceptives on serum dehydroepiandrosterone sulfate (DHEAS) are related to alterations in serum albumin rather than to changes in adrenocortical steroid secretion. Scand J Clin Lab Invest 62:361–368PubMedCrossRefGoogle Scholar
  36. 36.
    Miller KK, Lawson EA, Mathur V, Wexler TL, Meenaghan E, Misra M et al (2007) Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. J Clin Endocrinol Metab 92:1334–1339PubMedCrossRefGoogle Scholar
  37. 37.
    Lawson EA, Misra M, Meenaghan E, Rosenblum L, Donoho DA, Herzog D (2009) Adrenal glucocorticoid and androgen precursor dissociation in anorexia nervosa. J Clin Endocrinol Metab 94:1367–1371PubMedCrossRefGoogle Scholar
  38. 38.
    Miller KK, Grieco KA, Klibanski A (2005) Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab 90:1428–1433PubMedCrossRefGoogle Scholar
  39. 39.
    Panjari M, Davis SR (2010) DHEA for postmenopausal women: a review of the evidence. Maturitas 66:172–179PubMedCrossRefGoogle Scholar
  40. 40.
    Labrie F, Luu-The V, Bélanger A, Lin SX, Simard J, Pelletier G et al (2005) Is dehydroepiandrosterone a hormone? J Endocrinol 187:169–196PubMedCrossRefGoogle Scholar
  41. 41.
    Davis SR, Shah SM, McKenzie DP, Kulkarni J, Davison SL, Bell RJ (2008) Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metab 93:801–808PubMedCrossRefGoogle Scholar
  42. 42.
    Genazzani AR, Pluchino N, Begliuomini S, Stomati M, Bernardi F, Pieri M et al (2006) Long-term low-dose oral administration of dehydroepiandrosterone modulates adrenal response to adrenocorticotropic hormone in early and late postmenopausal women. Gynecol Endocrinol 22:627–635PubMedCrossRefGoogle Scholar
  43. 43.
    Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR (2003) Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 144:3449–3455PubMedCrossRefGoogle Scholar
  44. 44.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL et al (2009) Serum steroid levels during 12-weeks intravaginal dehydroepiandrosterone administration. Menopause 16:897–906PubMedCrossRefGoogle Scholar
  45. 45.
    Pluchino N, Ninni F, Stomati M, Freschi L, Casarosa E, Valentino V et al (2008) One-year therapy with 10 mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas 20:293–303CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Nicola Pluchino
    • 1
  • Arianna Carmignani
    • 1
  • Alessandra Cubeddu
    • 1
  • Anna Santoro
    • 1
  • Vito Cela
    • 1
  • Tania Errasti Alcalà
    • 1
  1. 1.Department of Reproductive Medicine and Child Development, Division of Gynecology and ObstetricsUniversity of PisaPisaItaly

Personalised recommendations